Table 3 Post hoc analyses of the SUPERIOR trial
|  | Placebo (n = 47) | Meropenem (n = 44) | % difference (95% CIs) | Odds ratio (95% CIs) | p value |
|---|---|---|---|---|---|
Delta SOFA 72 h without LOCF, median (Q1 to Q3) | 0 (− 1 to 1)a |  − 1 (− 2 to 0)b | NA | NA | 0.005 |
Delta SOFA 96 h without LOCF, median (Q1 to Q3) | 0 (− 1 to 0)c |  − 1 (− 2 to 0)d | NA | NA | 0.033 |
Modified empiric treatment after culture results, n (%) | 24 (51.1) | 18 (40.9) | 10.2 (− 10 to 29.2) | 0.66 (0.29 to 1.52) | 0.402 |
 Escalation, n (%) | 8 (17) | 8 (18.2) | 1.1 (− 14.6 to 17.2) | 1.08 (0.37 to 3.2) | 1.00 |
 De-escalation, n (%) | 16 (34) | 10 (22.7) | 11.3 (− 7.3 to 28.7) | 0.57 (0.23 to 1.44) | 0.255 |
 No change, n (%) | 23 (48.9) | 26 (59.1) | 10.2 (− 10 to 29.2) | 1.51 (0.66 to 3.5) | 0.402 |
Source control performed, n (%) | 4 (8.5) | 6 (13.6) | 5.1 (− 8.4 to 19.2) | 1.70 (0.45 to 6.5) | 0.514 |
 Renal abscess drainage, n (%) | 2 (4.3) | 1 (2.3) | 2 (− 8 to 12.2) | 0.52 (0.05 to 6) | 1.00 |
 Pleural effusion/ empyema drainage, n (%) | 2 (4.3) | 1 (2.3) | 2 (− 8 to 12.2) | 0.52 (0.05 to 6) | 1.00 |
 Pigtail removal, n (%) | 0 | 1 (2.3) | 2.3 (− 5.5 to 11.8) | 0.5 (0.4 to 0.6) | 0.484 |
 Percutaneous transhepatic drainage, n (%) | 0 | 1 (2.3) | 2.3 (− 5.5 to 11.8) | 0.5 (0.4 to 0.6) | 0.484 |
 Gangrene toe amputation, n (%) | 0 | 1 (2.3) | 2.3 (− 5.5 to 11.8) | 0.5 (0.4 to 0.6) | 0.484 |
 Surgery for diverticulitis, n (%) | 0 | 1 (2.3) | 2.3 (− 5.5 to 11.8) | 0.5 (0.4 to 0.6) | 0.484 |
Need for ICU hospitalization, n (%) | 1 (2.1) | 1 (2.3) | 0.15 (− 9 to 10) | 1.05 (0.1 to 17.3) | 1.00 |